NMPA Unveils 82nd Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has announced the release of the 82nd batch of...
Hainan Province Unveils Ambitious Three-Year Plan for Digital Health Innovation and Economy Expansion
HAIKOU—The People’s Government of Hainan Province has unveiled the “Hainan Province’s Three Year Action Plan...
China Expands Medical Insurance Coverage to Include Assisted Reproductive Technology in 19 Regions
BEIJING—As of September 1, 2024, a total of 19 provinces, municipalities, and the Xinjiang Production...
BioAge Labs Taps Former GSK CEO Jean-Pierre Garnier as Chairman
NEW YORK—BioAge Labs, a US-based biotechnology company specializing in anti-aging therapies, has announced the appointment...
China’s NMPA Suspends Dr. Reddy’s Atomoxetine Imports Amid Quality Concerns
BEIJING—The National Medical Products Administration (NMPA) has issued a notification to immediately suspend the import,...
Roche Diagnostics to Double Down on China with RMB 3 Billion Suzhou Plant Expansion
SUZHOU—Roche Diagnostics, the Swiss healthcare giant, has entered into a new investment agreement with the...
WuXi Biologics to Acquire Full Control of Vaccine Contract Services Subsidiary for $108.5 Million
HONG KONG—WuXi Biologics (HKG: 2269), a leading global open biopharmaceutical technology platform company, has announced...
Tiantan Biological to Acquire Wuhan Zhongyuan Ruide for $185 Million, Expanding Plasma Resources
BEIJING—Beijing Tiantan Biological Products Co., Ltd (Tiantan Biological, SHA: 600161) has announced that its subsidiary,...
Junshi Biosciences Logs 17.37% Revenue Growth in 2024H1, Fueled by Loqtorzi Sales Surge
SHANGHAI—Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its financial results for...
MicroPort Medical Reports 17% Revenue Growth in 2024H1, Driven by Subsidiaries’ Performance
HONG KONG—MicroPort Medical Science and Technology Co., Ltd (HKG: 0853), a leading medical device company,...
Sino Medical Sciences Secures Hong Kong Approval for Coronary Balloon Dilation Catheter
HONG KONG—Sino Medical Sciences Technology Inc., (SHA: 688108), a leading medical device company based in...
Hutchmed Withdraws Fruquintinib’s New Indication Application in China, Seeks Alternative Regulatory Path
HONG KONG—Hutchmed (HKG: 0013) has announced its decision to proactively withdraw the new indication application...
J&J Files NDA for FcRn Blocker Nipocalimab, Targets Myasthenia Gravis Market
US-based Johnson & Johnson (NYSE: JNJ) has made a global first New Drug Application (NDA)...
Merck Ends Phase III Keytruda Studies in NSCLC and cSCC Due to Insufficient Results
US-based Merck, Sharp & Dohme Inc. (NYSE: MRK) announced the discontinuation of two Phase III...
BioMarin to Cut 225 Jobs Amid Challenges in Gene Therapy Commercialization
US-based BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is navigating a challenging period marked by difficulties in...
MicroPort CardioFlow to Acquire RMB 380 Million Shanghai Assets for Global HQ Expansion
China-based MicroPort Scientific Corp. (HKG: 0853) has announced that its spin-off, MicroPort CardioFlow Medtech Co.,...
Tonghua Golden-Horse, UCB Seek China Approvals for Alzheimer’s, Myasthenia Gravis Drugs
China’s Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. and Belgium-based UCB (FRA: UNC) are seeking marketing...
Dizal Pharmaceutical’s Financial Turnaround Continues with 33% Net Loss Reduction in H1 2024
Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its...
Doma Biopharmaceutical Receives FDA Clearance for Phase I Trial of EGFR-MET Targeting ADC, DM005
Doma Biopharmaceutical (Suzhou) Co., Ltd, a Chinese pharmaceutical firm, has received approval from the U.S....
Jiyuan Biotechnology’s Stem Cell Therapy for Type 2 Diabetes Gains NMPA Tacit Approval for Clinical Trials
BEIJING—Jiyuan Biotechnology, a leading Chinese biopharmaceutical company, has secured tacit clinical trial approval from the...